Abstract Background/Introduction Tricuspid regurgitation (TR) is associated with heart failure and reduced survival. Within a short-time period, transcatheter tricuspid valve repair or replacement (TTVR)(TTVr) for TR has evolved from innovation to clinical reality. Objectives The present study’s aim is to provide 1-year results between TR patients treated with TTVR and TTVr compared to untreated patients, in terms of cardiac survival, rehospitalization, right-side heart failure symptoms development, and NYHA improvement. Methods 77 patients (pts) have been prospectively inserted into a dedicated database from January 2020 till January 2023. 26 pts (33.8%) have been treated with TTVR/r (Treated Group-TG) and 51 pts (66.2%) have been left untreated with medical therapy (MT) optimization (UN-TreatedGroup-UNTG). Results Analyzing the cardiac death between the 2 groups, there was a significant statistical difference since TG has less incidence of exitus in the general population (p-value =0,05). Concerning HF hospitalization, TG has a lower incidence with a p-value =0,005, Figure 2. In TG there was a significant improvement in NYHA class at FUP (p-value =0,001) as well as an improvement in right-side HF symptoms (p-value =0,001). Conclusion This study shows that treatment in the case of TR with right-side HF has a positive impact on cardiac death and HF hospitalization at 1 year. As well as there is a significant improvement in clinical and echocardiographic status at FUP in the treated group.